H.C. Wainwright ‘encouraged’ by VYNE Therapeutics VYN202 update

After VYNE Therapeutics (VYNE) provided an update on its VYN202 program following the recent FDA clinical hold on the Phase 1b trial in moderate-to-severe plaque psoriasis, H.C. Wainwright notes that VYNE decided to unblind the data from the enrolled subjects following the hold. The firm, which says it is “encouraged by the meaningful improvements seen in patients treated with VYN202,” maintains a Buy rating and $4.50 price target on VYNE shares.